MedTrace Logo

Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects

NCT06639555 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-10-15

No results posted yet for this study

Summary

Study of the effectiveness of the application of regenerative therapy with autogenous, platelet-rich plasma in vertical defects Investigation of the effectiveness of the application of regenerative therapy with enamel matrix derivatives in vertical bone defects Study of the effectiveness of the application of guided tissue regeneration in vertical bone defects with Barrier membrane and Barrier membrane and autogenous platelet-rich plasma

Conditions

  • Vertical Alveolar Bone Loss

Interventions

PROCEDURE

PRP( platelet rich plasma)

regenerative therapy with PRP for vertical bone defects

PROCEDURE

EMD (Enamel Matrix Derivative)

regenerative therapy with EMD for vertical bone defects

PROCEDURE

Guided Tissue Regeneration (barrier membrane)

guided tissue regeneration with barrier membrane alone for vertical bone defects

PROCEDURE

Guided Tissue Regeneration(barrier membrane and PRP)

guided tissue regeneration with barrier membrane and PRP for vertical bone defects

Sponsors & Collaborators

  • Tsvetalina Gerova-Vatsova

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-24
Primary Completion
2023-02-15
Completion
2023-08-15

Countries

  • Bulgaria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06639555 on ClinicalTrials.gov